IDEAYA Biosciences’ (IDYA) “Market Outperform” Rating Reiterated at Citizens Jmp

Citizens Jmp reiterated their market outperform rating on shares of IDEAYA Biosciences (NASDAQ:IDYA) in a report published on Tuesday,Benzinga reports. Citizens Jmp currently has a $42.00 price objective on the stock.

IDYA has been the subject of a number of other research reports. Wedbush upped their price objective on shares of IDEAYA Biosciences from $58.00 to $60.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Friday, July 17th. Cantor Fitzgerald reissued an “overweight” rating on shares of IDEAYA Biosciences in a research note on Friday, May 22nd. Royal Bank Of Canada lowered their price target on IDEAYA Biosciences from $53.00 to $48.00 and set an “outperform” rating for the company in a report on Tuesday, July 7th. Finally, Citigroup restated a “market outperform” rating on shares of IDEAYA Biosciences in a report on Tuesday. Fifteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.87.

IDEAYA Biosciences Stock Performance

Shares of NASDAQ IDYA opened at $39.97 on Tuesday. The stock has a market cap of $3.51 billion, a P/E ratio of -20.60 and a beta of -0.07. The firm has a 50 day moving average price of $37.54 and a 200 day moving average price of $33.41. IDEAYA Biosciences has a 52-week low of $23.23 and a 52-week high of $42.68.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, August 4th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.06) by ($0.16). The firm had revenue of $8.86 million during the quarter, compared to the consensus estimate of $8.02 million. IDEAYA Biosciences had a negative net margin of 75.93% and a negative return on equity of 16.73%. The firm’s revenue for the quarter was up 8800.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.88) EPS. Analysts predict that IDEAYA Biosciences will post -4.38 earnings per share for the current fiscal year.

Insider Buying and Selling at IDEAYA Biosciences

In related news, CAO Andres Ruiz Briseno sold 9,550 shares of IDEAYA Biosciences stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total value of $382,095.50. Following the sale, the chief accounting officer owned 26,466 shares of the company’s stock, valued at approximately $1,058,904.66. The trade was a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC increased its position in shares of IDEAYA Biosciences by 171.1% during the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock worth $32,000 after purchasing an additional 580 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of IDEAYA Biosciences in the 2nd quarter valued at approximately $43,000. ANTIPODES PARTNERS Ltd grew its stake in shares of IDEAYA Biosciences by 49.4% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after buying an additional 380 shares in the last quarter. Global Retirement Partners LLC bought a new position in shares of IDEAYA Biosciences in the fourth quarter valued at $61,000. Finally, Nykredit A S bought a new position in shares of IDEAYA Biosciences in the second quarter valued at $76,000. 98.29% of the stock is currently owned by institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.